News for Regeneron Pharmaceuticals Stock (REGN)

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club

Investors Business Daily • 06/12/24

The Schall Law Firm Has Begun An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Make Contact

Accesswire • 06/11/24

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion

Zacks Investment Research • 06/11/24

Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

Seeking Alpha • 06/11/24

Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

GlobeNewsWire • 06/11/24

2 Biotech Stocks For Your June 2024 Watchlist

Stockmarketcom • 06/11/24

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

Accesswire • 06/09/24

The Schall Law Firm Has Begun An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Contact Them

Accesswire • 06/09/24

The Schall Law Firm Has Initiated A Probe Into Allegations Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Urges Investors Who Have Experienced Losses To Reach Out

Accesswire • 06/08/24

The Schall Law Firm Announces An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Get In Touch

Accesswire • 06/07/24

Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire • 06/07/24

Stock Split Watch: 3 Growth Stocks That Could Be Next

The Motley Fool • 06/07/24

The Schall Law Firm Declares An Inquiry Into Allegations Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Urges Investors Who Have Incurred Losses To Reach Out

Accesswire • 06/06/24

The Schall Law Firm Announces An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors With Losses To Make Contact

Accesswire • 06/05/24

Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)

Seeking Alpha • 06/05/24

Health Care Stocks Show Relative Strength as S&P 500 Stalls

Zacks Investment Research • 06/04/24

3 Stocks to Watch in Active Growth ETF FDG

ETF Trends • 06/04/24

The Schall Law Firm Declares an Inquiry into Accusations Against Regeneron Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out

Accesswire • 06/04/24

REGN CRUCIAL INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/03/24

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/02/24

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/01/24

ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/31/24

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewsWire • 05/31/24

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewsWire • 05/31/24

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

GlobeNewsWire • 05/31/24